General information about company	
Scrip code	524372
NSE Symbol	ORCHIDPHAR
MSEI Symbol	NA
ISIN	INE191A01019
Name of the entity	ORCHID PHARMA LTD
Date of start of financial year	01-04-2019
Date of end of financial year	31-03-2020
Reporting Quarter	Quarterly
Date of Report	31-12-2019
Risk management committee	Not Applicable
Market Capitalisation as per immediate previous Financial Year	Any other

Annexure I

Annexure I to be submitted by listed entity on quarterly basis

I. Composition of Board of Directors

Disclosure of notes on composition of board of directors explanatory	Textual Information(1)
Wether the listed entity has a Regular Chairperson	No
Whether Chairperson is related to MD or CEO	No

ame of the Director	PAN	DIN	Category 1 of directors	Category 2 of directors	Category 3 of directors	Date of Birth	Whether special resolution passed? [Refer Reg. 17(1A) of Listing Regulations]	Date of passing special resolution	Initial Date of appointment	Date of Re-appointment	Date of cessation	Tenure of director (in months)	No of Directorship in listed entities including this listed entity (Refer Regulation 17A of Listing Regulations)	No of Independent Directorship in listed entities including this listed entity (Refer Regulation 17A(1) of Listing Regulations	Number of memberships in Audit/ Stakeholder Committee(s) including this listed entity (Refer Regulation 26(1) of Listing Regulations)	No of post of Chairperson in Audit/ Stakeholder Committee held in listed entities including this listed entity (Refer Regulation 26(1) of Listing Regulations)	Notes f not providi PAN
ghavendra o	AAAPR4013J	00010096	Executive Director	Not Applicable	CEO-MD	22-07-1958	NA		01-07-1992	01-07-2017		30	1	0	1	0	

Text Block	
Textual Information(1)	The Corporate Insolvency Resolution Process (CIRP) was initiated for the company with effect from August 17, 2017. Subsequent to the commencement of the CIRP, the powers of the Board of Directors stands suspended. The Hon'ble National Company Law Tribunal, Chennai Bench (NCLT) had passed an order on October 10, 2018. As per the Hon'ble NCLT order, the Resolution Professional shall discharge the functions of the Company as per the instructions of the interim Monitoring Committee (iMC) constituted in accordance with the order, until further orders. Further, pursuant to the order of the Hon'ble NCLT dated February 28,2019, the Resolution Professional and the Committee of Creditors are reinstated and will discharge their functions as before during this CIRP period. Shri K N Venkatasubramanian, Chairman and Independent Director had resigned with effect from October 13, 2017 and Shri R Kannan, Independent Director had resigned with effect from December 27, 2017. Further, Smt. SoundaraKumar, Nominee Director-SBI had resigned with effect from September 10, 2018 and the nomination of Shri Ramakrishna Eda, Nominee Director-IDBI Bank Ltd was withdrawn with effect from September 18, 2018. Pursuant to the commencement of the CIRP and the resignation of Directors, the reconstitution of the Board and committees is pending. The Honble NCLT by its order dated June 27, 2019 (received by the Company on June 28, 2019) has approved the resolution plan submitted by Dhanuka Laboratories Limited under Section 31 of the Insolvency and Bankruptcy Code, 2016. Thereafter, one of the unsuccessful bidder have already filed an application before the Hon'ble NCLT seeking to consider his Resolution plan by the RP and COC which was dismissed by the Honble NCLT on June 27, 2019. Pursuant to the said order of dismissal the said Resolution Applicant had preferred an appeal before the Honble National Company Law Appellate Tribunal (NCLAT), and the said matter was listed for hearing on July 26, 2019 and the Honble NCLAT passed an order of Stay for the order dated 27.06.2019 passed by the Honble NCLT Chennai Bench. The matter was heard by NCLAT, New Delhi in August 2019 and on November 13, 2019. The Honble NCLAT, New Delhi has set aside the Order passed by the Honble NCLT, Chennai approving the Resolution plan and remitted the matter back to Honble NCLT, Chennai for a decision in accordance with law. A copy of the Order passed by NCLAT, New Delhi on November 13, 2019 is enclosed for your reference. State Bank of India, one of the members of the financial creditors of Orchid Pharma Ltd. has preferred an appeal before the Honble Supreme Court of India against the Order dated November 13, 2019 of NCLAT as stated herein above. The case was listed in Supreme Court on December 06th, 2019 and they have granted a stay of further proceedings on this matter. The management and the operations continues to be vested with the Resolution Professional to keep the Company as a going concern.

Annexure 1	
II. Composition of Committees	
Disclosure of notes on composition of committees explanatory	Textual Information(1)

Annexure 1 Text Block	
Textual Information(1)	The Corporate Insolvency Resolution Process (CIRP) was initiated for the company with effect from August 17, 2017. Subsequent to the commencement of the CIRP, the powers of the Board of Directors stands suspended. The Hon'ble National Company Law Tribunal, Chennai Bench (NCLT) had passed an order on October 10, 2018. As per the Hon'ble NCLT order, the Resolution Professional shall discharge the functions of the Company as per the instructions of the interim Monitoring Committee (iMC) constituted in accordance with the order, until further orders. Further, pursuant to the order of the Hon'ble NCLT dated February 28,2019, the Resolution Professional and the Committee of Creditors are reinstated and will discharge their functions as before during this CIRP period. Shri K N Venkatasubramanian, Chairman and Independent Director had resigned with effect from October 13, 2017 and Shri R Kannan, Independent Director had resigned with effect from December 27, 2017. Further, Smt. SoundaraKumar, Nominee Director-SBI had resigned with effect from September 10, 2018 and the nomination of Shri Ramakrishna Eda, Nominee Director-IDBI Bank Ltd was withdrawn with effect from September 18, 2018. Pursuant to the commencement of the CIRP and the resignation of Directors, the reconstitution of the Board and committees is pending. The Honble NCLT by its order dated June 27, 2019 (received by the Company on June 28, 2019) has approved the resolution plan submitted by Dhanuka Laboratories Limited under Section 31 of the Insolvency and Bankruptcy Code, 2016. Thereafter, one of the unsuccessful bidder have already filed an application before the Hon'ble NCLT seeking to consider his Resolution plan by the RP and COC which was dismissed by the Honble NCLT on June 27, 2019. Pursuant to the said order of dismissal the said Resolution Applicant had preferred an appeal before the Honble National Company Law Appellate Tribunal (NCLAT), and the said matter was listed for hearing on July 26, 2019 and the Honble NCLAT passed an order of Stay for the order dated 27.06.2019 passed by the Honble NCLT Chennai Bench. The matter was heard by NCLAT, New Delhi in August 2019 and on November 13, 2019. The Honble NCLAT, New Delhi has set aside the Order passed by the Honble NCLT, Chennai approving the Resolution plan and remitted the matter back to Honble NCLT, Chennai for a decision in accordance with law. A copy of the Order passed by NCLAT, New Delhi on November 13, 2019 is enclosed for your reference. State Bank of India, one of the members of the financial creditors of Orchid Pharma Ltd. has preferred an appeal before the Honble Supreme Court of India against the Order dated November 13, 2019 of NCLAT as stated herein above. The case was listed in Supreme Court on December 06th, 2019 and they have granted a stay of further proceedings on this matter. The management and the operations continues to be vested with the Resolution Professional to keep the Company as a going concern.

Audit Committee Details							
Whether the Audit Committee has a Regular Chairperson					No		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks

Nomination and remuneration committee							
Whether the Nomination and remuneration committee has a Regular Chairperson					No		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks

Stakeholders Relationship Committee							
Whether the Stakeholders Relationship Committee has a Regular Chairperson					No		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks
1	00010096	K Raghavendra Rao	Executive Director	Member	01-07-2017		

Risk Management Committee							
Whether the Risk Management Committee has a Regular Chairperson							
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks

Corporate Social Responsibility Committee							
Whether the Corporate Social Responsibility Committee has a Regular Chairperson					No		
Sr	DIN Number	Name of Committee members	Category 1 of directors	Category 2 of directors	Date of Appointment	Date of Cessation	Remarks

Other Committee						
Sr	DIN Number	Name of Committee members	Name of other committee	Category 1 of directors	Category 2 of directors	Remarks

Annexure 1	
Annexure 1	
III. Meeting of Board of Directors	
Disclosure of notes on meeting of board of directors explanatory	Textual Information(1)

Text Block	
Textual Information(1)	The Corporate Insolvency Resolution Process (CIRP) was initiated for the company with effect from August 17, 2017. Subsequent to the commencement of the CIRP, the powers of the Board of Directors stand suspended. The Hon'ble National Company Law Tribunal, Chennai Bench (NCLT) had passed an order on October 10, 2018. As per the Hon'ble NCLT order, the Resolution Professional shall discharge the functions of the Company as per the instructions of the interim Monitoring Committee (iMC) constituted in accordance with the order, until further orders. Further, pursuant to the order of the Hon'ble NCLT dated February 28, 2019, the Resolution Professional and the Committee of Creditors was to discharge their functions as before during this CIRP period. The details of the Monitoring Committee and Committee of Creditors meetings held during the quarter October 01, 2019 - December 31, 2019 are enumerated below: 1. 4th Monitoring Committee : 19th December 2019 2. 22nd Committee of Creditors: 16th November 2019 3. 23rd Committee of Creditors: 02nd December 2019 The details of meeting convened by the Resolution Professional during the quarter October 01, 2019 - December 31, 2019 to consider and take on record the Unaudited financial results for the Quarter ended September 30, 2019 are enumerated below: 10th meeting convened by the Resolution Professional on November 14, 2019.

Annexure 1	
IV. Meeting of Committees	
Disclosure of notes on meeting of committees explanatory	Textual Information(1)

Text Block	
Textual Information(1)	The Corporate Insolvency Resolution Process (CIRP) was initiated for the company with effect from August 17, 2017. Subsequent to the commencement of the CIRP, the powers of the Board of Directors stands suspended. The Hon'ble National Company Law Tribunal, Chennai Bench (NCLT) had passed an order on October 10, 2018. As per the Hon'ble NCLT order, the Resolution Professional shall discharge the functions of the Company as per the instructions of the interim Monitoring Committee (iMC) constituted in accordance with the order, until further orders. Further, pursuant to the order of the Hon'ble NCLT dated February 28,2019, the Resolution Professional and the Committee of Creditors are reinstated and will discharge their functions as before during this CIRP period. Shri K N Venkatasubramanian, Chairman and Independent Director had resigned with effect from October 13, 2017 and Shri R Kannan, Independent Director had resigned with effect from December 27, 2017. Further, Smt. SoundaraKumar, Nominee Director-SBI had resigned with effect from September 10, 2018 and the nomination of Shri Ramakrishna Eda, Nominee Director-IDBI Bank Ltd was withdrawn with effect from September 18, 2018. Pursuant to the commencement of the CIRP and the resignation of Directors, the reconstitution of the Board and committees is pending. The Honble NCLT by its order dated June 27, 2019 (received by the Company on June 28, 2019) has approved the resolution plan submitted by Dhanuka Laboratories Limited under Section 31 of the Insolvency and Bankruptcy Code, 2016. Thereafter, one of the unsuccessful bidder have already filed an application before the Hon'ble NCLT seeking to consider his Resolution plan by the RP and COC which was dismissed by the Honble NCLT on June 27, 2019. Pursuant to the said order of dismissal the said Resolution Applicant had preferred an appeal before the Honble National Company Law Appellate Tribunal (NCLAT), and the said matter was listed for hearing on July 26, 2019 and the Honble NCLAT passed an order of Stay for the order dated 27.06.2019 passed by the Honble NCLT Chennai Bench. The matter was heard by NCLAT, New Delhi in August 2019 and on November 13, 2019. The Honble NCLAT, New Delhi has set aside the Order passed by the Honble NCLT, Chennai approving the Resolution plan and remitted the matter back to Honble NCLT, Chennai for a decision in accordance with law. A copy of the Order passed by NCLAT, New Delhi on November 13, 2019 is enclosed for your reference. State Bank of India, one of the members of the financial creditors of Orchid Pharma Ltd. has preferred an appeal before the Honble Supreme Court of India against the Order dated November 13, 2019 of NCLAT as stated herein above. The case was listed in Supreme Court on December 06th, 2019 and they have granted a stay of further proceedings on this matter. The management and the operations continues to be vested with the Resolution Professional to keep the Company as a going concern. Given these circumstances, the reconstitution of the Board and the committees in accordance with the SEBI (LODR) Regulations, 2015 can be considered only after the completion of CIRP.

Annexure 1			
V. Related Party Transactions			
Sr	Subject	Compliance status (Yes/No/NA)	If status is “No” details of non-compliance may be given here.
1	Whether prior approval of audit committee obtained	No	The Company is under Corporate Insolvency Resolution Process. The Powers of the Board stands suspended. The Management of the affairs of the company is entrusted with the Resolution Professional.
2	Whether shareholder approval obtained for material RPT	NA	
3	Whether details of RPT entered into pursuant to omnibus approval have been reviewed by Audit Committee	NA	

Annexure 1

VI. Affirmations

Sr	Subject	Compliance status (Yes/No)
1	The composition of Board of Directors is in terms of SEBI (Listing obligations and disclosure requirements) Regulations, 2015	No
2	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015 a. Audit Committee	No
3	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. b. Nomination & remuneration committee	No
4	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. c. Stakeholders relationship committee	No
5	The composition of the following committees is in terms of SEBI(Listing obligations and disclosure requirements) Regulations, 2015. d. Risk management committee (applicable to the top 500 listed entities)	NA
6	The committee members have been made aware of their powers, role and responsibilities as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	No
7	The meetings of the board of directors and the above committees have been conducted in the manner as specified in SEBI (Listing obligations and disclosure requirements) Regulations, 2015.	No
8	This report and/or the report submitted in the previous quarter has been placed before Board of Directors.	No

Annexure 1		
Sr	Subject	Compliance status
1	Name of signatory	S Mani
2	Designation	Compliance Officer

Signatory Details	
Name of signatory	S Mani
Designation of person	Compliance Officer
Place	chennai
Date	14-01-2020